Cerivastatin (sodium salt)

Cerivastatin (sodium salt) (CAS No.: 143201-11-0) is a synthetic statin-class lipid-lowering agent that functions as a highly potent, competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, a key rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. By blocking this pathway with nanomolar affinity, it effectively reduces intracellular cholesterol production and lowers low-density lipoprotein levels, making it a valuable tool for studying lipid metabolism and cardiovascular biology. In vitro, cerivastatin exhibits strong inhibitory activity in the low nanomolar range against its primary enzymatic target and suppresses cholesterol synthesis and proliferation in vascular smooth muscle and arterial myocytes, while also attenuating cell migration processes associated with vascular remodeling. Beyond its canonical role, cerivastatin has been shown to modulate small GTPase signaling, particularly through inhibition of RhoA activity, thereby reducing proliferation and invasiveness of certain cancer cell lines such as MDA-MB-231, highlighting its relevance in tumor biology and signaling pathway research. In vivo studies further demonstrate its capacity to reduce circulating lipid levels, inhibit cholesterol accumulation in arterial tissues, and stabilize atherosclerotic plaques in preclinical models. As such, cerivastatin sodium is widely utilized in studies of cholesterol metabolism, atherosclerosis, vascular cell function, and exploratory anti-cancer mechanisms, with experimental concentrations and dosing regimens varying depending on specific cellular or animal model systems and research objectives.